Literature DB >> 2451610

Magnetic resonance (MR) imaging of prostatic tumours, a comparison with X-ray CT and transrectal sonography (TRS).

A Bockisch1, N Jäger, H J Biersack, W Vahlensieck, B Hünermann, H G Schmitz, R Knopp, F Christ, C Winkler.   

Abstract

A total of 7 healthy volunteers and 31 patients have been examined clinically, by MRI, TRS, and biopsy. In those patients with established carcinoma, a CT examination was also performed. For the MRI study, a superconducting MR 2000 imager (Picker International) operated at 0.15 T was used with multiplanar SE and IR sequences. SE sequences with long echo times detected prostatitis, adenoma and carcinoma of the prostate with a high degree of sensitivity. However, at present, differentiation between adenoma, prostatitis and carcinoma is not possible with sufficient accuracy. In these studies we were unable to establish a correlation between the signal pattern and staging and/or grading of the carcinoma. Reliable diagnosis of a prostate carcinoma still requires a biopsy. Because of the high soft tissue contrast and the possibility of selecting any orientation for the plane under investigation, however, MRI represents an improvement in the preoperative diagnosis of local spread.

Entities:  

Mesh:

Year:  1988        PMID: 2451610

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  3 in total

1.  Magnetic resonance imaging in oncology.

Authors:  J E Husband; R Guy
Journal:  Gut       Date:  1992-12       Impact factor: 23.059

Review 2.  MRI for men undergoing active surveillance or with rising PSA and negative biopsies.

Authors:  Orit Raz; Masoom Haider; John Trachtenberg; Dan Leibovici; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2010-10       Impact factor: 14.432

3.  Evaluation of 42 patients with chronic abacterial prostatitis: are there any underlying correctable pathologies?

Authors:  M K Atilla; H Sargin; O Odabaş; Y Yilmaz; S Aydin
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.